Maresin 1 attenuates neuroinflammation in a mouse model of perioperative neurocognitive disorders

T. Yang1,3, G. Xu1, P. T. Newton1, A. S. Chagin1,7, S. Mkrtchian1, M. Carlström1, X.-M. Zhang2, R. A. Harris2, M. Cooter8, M. Berger4,5,8, K. R. Maddipati9, K. Akassoglou10,11 and N. Terrando1,6,8,*

1Department of Physiology and Pharmacology, Stockholm, Sweden, 2Applied Immunology & Immunotherapy, Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Division of Nephrology, Durham, NC, USA, 4Center for Cognitive Neuroscience, Center for the Study of Aging & Human Development, Durham, NC, USA, 5Center for the Study of Aging & Human Development, Durham, NC, USA, 6Center for Translational Pain Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA, 7Institute for Regenerative Medicine, Sechenov First Moscow State Medical University, Moscow, Russian Federation, 8Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA, 9Department of Pathology-Bioactive Lipids Research Program, Wayne State University, Detroit, MI, USA, 10Gladstone Institutes, San Francisco, CA, USA and 11Department of Neurology, University of California San Francisco, San Francisco, CA, USA

*Corresponding author. E-mail: niccolo.terrando@duke.edu

This article is accompanied by an editorial: Specialised pro-resolving mediators: the magic bullet for perioperative neurocognitive disorders? by Li et al., Br J Anaesth 2019;122:292–294, doi: https://doi.org/10.1016/j.bja.2018.11.020.

Abstract

Background: Resolution of inflammation is an active and dynamic process after surgery. Maresin 1 (MaR1) is one of a growing number of specialised pro-resolving lipids biosynthesised by macrophages that regulates acute inflammation. We investigated the effects of MaR1 on postoperative neuroinflammation, macrophage activity, and cognitive function in mice.

Methods: Adult male C57BL/6 (n=111) and Ccr2Cre+/Cx3cr1GFP+/ (n=54) mice were treated with MaR1 before undergoing anaesthesia and orthopaedic surgery. Systemic inflammatory changes, bone healing, neuroinflammation, and cognition were assessed at different time points. MaR1 protective effects were also evaluated using bone marrow derived macrophage cultures.

Results: MaR1 exerted potent systemic anti-inflammatory effects without impairing fracture healing. Prophylaxis with MaR1 prevented surgery-induced gial activation and opening of the blood–brain barrier. In Ccr2Cre+/Cx3cr1GFP+/ mice, fewer infiltrating macrophages were detected in the hippocampus after surgery with MaR1 prophylaxis, which resulted in improved memory function. MaR1 treatment also reduced expression of pro-inflammatory cell surface markers and cytokines in vitro cultured macrophages. MaR1 was detectable in the cerebrospinal fluid of older adults before and after surgery.

Conclusions: MaR1 exerts distinct anti-inflammatory and pro-resolving effects through regulation of macrophage infiltration, NF-κB signalling, and cytokine release after surgery. Future studies on the use of pro-resolving lipid mediators may inform novel approaches to treat neuroinflammation and postoperative neurocognitive disorders.
Acute inflammation and activation of the innate immune response are fundamental processes after tissue trauma or infection. Resolution of inflammation is an active and highly controlled process orchestrated by several molecules including omega-3-derived specialised pro-resolving mediators (SPMs). SPMs regulate the magnitude and duration of inflammation, limiting neutrophil infiltration and promoting efferocytosis. Failed resolution is a key component of several inflammatory conditions and is of considerable interest in translational biomedical research. Mareins (macrophage mediators in resolving inflammation) are a genus of resolution agonists biosynthesised from docosahexaenoic acid (DHA) by macrophages that display anti-inflammatory and pro-resolving actions by macrophages that display anti-inflammatory and pro-resolving cytokines. Marein 1 (MaR1; 7R,14S-dihydroxydocosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid) is a family of structurally distinct autacoids, which, together with lipoxins, resolvins, and protectins, stimulate general resolution signaling. Importantly, SPMs (including MaR1) boost self-limiting inflammatory processes and enhance bacterial clearance without being immunosuppressive. MaR1 was also shown to improve cognitive outcome in a murine model of orthopaedic surgery. We also provide preliminary evidence that MaR1 levels can be measured in human cerebrospinal fluid (CSF) before and after surgery, raising the possibility that MaR1 levels could potentially play a role in resolving postoperative neuroinflammation in the human CNS.

Methods

Mice

All experiments were performed in accordance with protocols approved by the local ethics committee for animal research in Sweden (Stockholm North Animal Ethics Board) and conform to the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines. Inbred C57BL/6 mice 10–14 weeks old were purchased from Charles River (Sulzfeld, Germany), and Ccr2RFP/−/Cx3cr1GFP/+ were bred at the Karolinska Institutet animal facility and used as described. Male mice were used in the experiments and housed four per cage under temperature- and humidity-controlled conditions with a 12 h light–dark cycle and provided food and water ad libitum. All experiments were performed during the light cycle.

Surgery

An experimental aseptic tibia fracture model was used as described. Anaesthesia was induced in a dedicated chamber with 5 vol% isoflurane (Abbott Scandinavia AB, Stockholm, Sweden) for 2 min, and an open stabilised tibia fracture of the left hind leg was performed under 2.1 vol% isoflurane for 10–12 min. Briefly, after shaving and disinfecting the surgical field, a longitudinal incision was made and the muscles were dissociated from the periosteum. A 0.38 mm pin was then inserted in the intramedullary canal and osteotomy was performed. The wound was irrigated and sutured using 6–0 prolene. During the procedure, non-invasive pulse oximetry (MouseSTAT™; Kent Scientific, Torrington, CT, USA), concentrations of O2, CO2, isoflurane (Capnomac Ultima; Datex-Ohmeda, Helsinki, Finland), and temperature (Harvard Apparatus, Holliston, MA, USA) were continuously monitored and maintained within the normal range. Analgesia (buprenorphine, 0.1 mg kg−1 s.c.) was given after anaesthesia induction and prophylaxis with MaR1 (Cayman Chemical, Ann Arbor, MI,
USA) was given at 2 μg ml⁻¹ in saline with 0.14% ethanol, i.p. (50 μl) 100 ng per mouse before skin incision. Control mice received analgesia (buprenorphine, 0.1 mg kg⁻¹ s.c.) and a bolus dose of 0.14% ethanol in saline.

**Cytokine detection**

Blood from C57BL/6 and Ccr2RFP/+/Cx3cr1GFP/−/+ mice was collected via cardiac puncture under deep isoflurane anaesthesia at 24 h, 72 h, and 14 days after surgery, centrifuged at 2000 g for 9 min at 4°C, aliquoted and stored at −80°C for further analysis. MesoScale Discovery Technology (Gaithersburg, MD, USA) was used to analyse inflammatory markers in plasma with a SECTOR Imager 2400 apparatus following the manufacturer’s instructions.

**Behavioural tests**

Contextual fear conditioning was performed in a dedicated chamber (Med Associates Inc., St Albans, VT, USA). Separate cohorts of C57BL/6 or Ccr2RFP/+/Cx3cr1GFP/−/+ mice were trained before surgery as described. Briefly, an initial exploratory saline (PBS) followed by 4% PFA in 0.1 M PBS at pH 7.4 (VWR International, meditation for 48 h. Brain tissue was freeze-mounted in optimal cutting temperature (OCT) embedding medium (VWR International), and 25 μm thick coronal sections were cut sequentially and mounted on Superfrost Plus slides (Menzel-Glaser). Sections were permeabilised in PBS with 0.5% Triton X-100 and blocked with 5% bovine serum albumin (BSA) in PBS for 60 min at room temperature to block non-specific binding. The following primary antibodies were used: rabbit anti-α1 globulin acrylamide protein (GFAP) (1:100, cat. #20334; Dako, Kista, Sweden), goat anti-α3-1 (1:2000, cat. #ab107159; Abcam, Cambridge, UK), rabbit anti-Claudin-5 (1:100, cat. #34-1600; Invitrogen, Stockholm, Sweden) and goat anti-mouse podocalyxin (1:200, cat. #AF1556; R&D Systems, Minneapolis, MN, USA) at 4°C overnight. For secondary detection, (goat anti-rat, goat anti-rabbit, donkey anti-goat) conjugated with Alexa Fluor dyes (405, 488, and 555) from Invitrogen (1:500) were used. Immunolabelled sections were coverslipped with Prolong Gold anti-fade reagent with 4',6-diamidino-2-phenylindole (DAPI; Invitrogen) and analysed by confocal microscopy (LSM5 Exci; Zeiss, Jena, Germany). Four high magnifications were chosen in three non-overlapping fields randomly acquired in hippocampal subregions using a counting frame size of 0.4 mm². Images were processed and the area of the astrocytes, microglia/macrophages quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The area of the selected cells was converted into a binary image using the dilation method and the cell outline measured. Total immunoreactivity was calculated as percentage area density defined as the number of pixels (positively stained areas) divided by the total number of pixels (sum of positively and negatively stained area) in the imaged field. Quantitative analyses were performed in a blinded manner.

**Bone marrow-derived macrophages**

**Primary culture**

Bone marrow-derived macrophages (BMDMs) were cultured as described with minor modifications. In brief, femoral and tibia bone-marrow cells from C57BL/6 mice were collected, and single-cell suspensions were prepared and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 20% heat-inactivated FBS, 100 U ml⁻¹ penicillin, 100 μg ml⁻¹ streptomycin, 2 mM l-glutamine (all reagents from Life Technologies, Stockholm, Sweden), and 20 ng ml⁻¹ rmM-CSF (recombinant mouse macrophage colony-stimulating factor; R&D Systems) for 8 days. Cells were harvested using 2 mM EDTA and seeded in 48-well plates at 5 × 10⁵ cells/well. Cells were then stimulated with 10 ng ml⁻¹ lipopolysaccharide (LPS) from Escherichia coli endotoxin (0111:B4, 10 ng ml⁻¹; Sigma-Aldrich, St. Louis, MO, USA), with or without MaR1 (10 nM) for 2 or 24 h, respectively. Nuclear factor-kappa B (NF-κB) activation (2 h after treatment) and nicotinamide adenine dinucleotide phosphate (NADPH) mediated superoxide generation (24 h after treatment) were then evaluated. Cultured medium was collected for measurement of tumour necrosis factor-alpha (TNF-α) using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Biosource Invitrogen, Carlsbad, CA, USA) with a sensitivity of <3 pg ml⁻¹. Separate batches of BMDMs were stimulated with LPS (10 ng ml⁻¹) or 20 ng ml⁻¹ recombinant mouse interleukin (IL)-1β, 10, and recombinant human transforming growth factor (TGF)-β1 (R&D Systems) for 24 h and macrophage activation surface marker expression was assessed using flow cytometry.

**NF-κB activation**

Cells were fixed with 4% PFA for 15 min at room temperature, blocked in 5% BSA in PBS containing 0.3% Triton X-100 for 1 h,
and stained with anti-phospho-NF-κB p65 (1:200, cat. #3033; Cell Signaling Technology, Danvers, MA, USA) for 24 h at 4°C. For secondary detection a goat anti-rabbit Cy3-conjugated secondary antibody (1:200; Jackson ImmunoResearch, Ely, UK) was used for 1.5 h at room temperature in the dark. Coverslips were then mounted using Prolong Gold antifade reagent with DAPI (Invitrogen). Four representative images per slice were taken with an Axioplan II epifluorescence microscope (Zeiss). Quantification was determined as the proportion of total cells exhibiting nuclear phospho-NF-κB p65.

**Superoxide generation**

Cells were incubated in Dulbecco’s PBS (DPBS) at 37°C for 10 min after treatment and detached by gently repeated pipetting. Cell suspensions were collected in detection tubes followed by addition of lucigenin (5 μM; Sigma) and NADPH (100 μM; Sigma). Superoxide generation was detected every 3 s for 3 min by chemiluminescence reaction using a Autolumat LB953 Multi-Tube Luminometer (Berthold Technologies, Germany).

**Flow cytometry**

Cells were detached with 2 mM EDTA for 45 min at 37°C, then stained with antibodies specific for CD86, PD-L1, PD-L2, and CD206, and isotype controls (all from BD Pharmingen, Stockholm, Sweden). Samples were detected using a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA), and Kahuzi version 1.1 software (Beckman Coulter) was used for analysis. The median fluorescence intensity (MFI) of CD86, PD-L1, PD-L2, and CD206 was quantified as the readout of macrophage activation.

**Gene expression analysis**

Mice were killed 72 h after surgery and perfused transcardially with ice-cold 0.1 M PBS to avoid blood contamination. The hippocampus was rapidly dissected on ice and stored at −80°C. Total RNA was then extracted using RNeasy Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. An Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) was used for the RNA quality control and the samples with RNA integrity number (RIN) higher than 5.5 were used for further microarray analysis. Hippocampal RNA was hybridised to the Affymetrix Mouse Gene 2.1 ST 16-Array Plate (Affymetrix, Santa Clara, CA, USA) at the Karolinska Institutet’s Bioinformatics and Expression core facility. The functional annotation tool from the Database for Annotation, Visualization, and Integrated Discovery (DAVID) software was used to identify gene ontology (GO) categories and biological pathways of differentially expressed genes. A cut-off at P<0.05 and fold change >2 or >1.5 was used for analysis. This dataset is deposited and available at GEO (submission number GSE115440).

**Human patient enrollment**

CSF samples were collected via lumbar puncture from 11 older adult subjects (age ≥60 yr) before, 24 h after, and 6 weeks after non-cardiac, non-neurological surgery. They were prospectively enrolled in the Markers of Alzheimer’s Disease and Neurocognitive Outcomes after Perioperative Care (MADCO-PC) study, which is registered with clinicaltrials.gov (NCT01993836) and approved by the Duke University Medical Center Institutional Review Board. All MADCO-PC subjects underwent informed consent before completing any study activities, and then completed a neurocognitive test battery before and 6 weeks after surgery. Patients were excluded if they were pregnant, taking anticoagulants in contravention of the American Society of Regional Anesthesia and Pain Medicine (ASRA) guidelines, taking chemotherapeutic drugs, or were correctional facility inmates.

**Perioperative CSF samples**

Before lumbar puncture, the lower back was sprayed with 20% benzocaine spray (available without prescription in the USA), and then an additional 2–5 ml of 1% lidocaine was injected subcutaneously at the planned lumbar puncture site. After waiting for several minutes, CSF samples were obtained via lumbar puncture at the L4–5 interspace (or one space more rostral or caudal) with a 25 g pencil point needle. First, 10 ml of CSF was gently aspirated with a 10 ml polypropylene syringe, and was then placed in a pre-chilled 15 ml polypropylene conical tube on ice. Within 1 h, this CSF sample was separated into 1 ml aliquots using low binding polypropylene pipette tips, which were then frozen at −80°C. Cognitive testing was performed, and continuous cognitive indices were calculated as described. As no prior study had measured MaR1 in human CSF, there were insufficient data to perform a sample size or power analysis calculation to evaluate how many patients (or samples) are necessary to determine MaR1 in human CSF. Thus, we simply used samples from 11 MADCO-PC subjects for this pilot study. Because a prior study that measured other lipid concentrations in human CSF found that several millilitres of CSF was necessary for successful detection of low abundance lipid molecules, we chose to measure MaR1 levels in 3 ml CSF from each subject’s sample time point.

**Human CSF lipidomic analysis**

CSF samples (three aliquots of 1 ml each per subject at each time point) were shipped via overnight express on dry ice to the Lipid Core Research Facility at Wayne State University (Detroit, MI, USA). Liquid chromatography mass spectrometry (LC-MS) grade methanol was added to the internal standard supplemented samples to a final concentration of 15%. Samples were sonicated in a bath sonicator for 2 min and left on ice for 1 h in the dark, and were applied to pre-conditioned C18 solid phase extraction cartridges (StrataX C18, Torrance, CA, USA, 30 mg; Phenomenex; conditioned with 2 ml methanol followed by 2 ml water containing 15% methanol), washed with 2 ml 15% methanol in water followed by 2 ml hexane, and dried under vacuum. Cartridges were eluted directly into high-performance liquid chromatography (HPLC) autosampler vials with 1 ml methanol containing 0.1% formic acid. Eluates were evaporated to dryness under a gentle stream of nitrogen while maintaining external temperature at 25°C. The dried residue was immediately reconstituted in methanol, vials flushed with nitrogen, capped, and stored at −80°C until analysis. At the time of LC-MS analysis, samples were thawed to room temperature and an equal volume of 25 mM aqueous ammonium acetate was added, vortex mixed, and loaded in the autosampler maintained at 15°C. HPLC is performed on a Prominence XR system (Shimadzu, Kyoto, Japan) using a Luna C18 (3 μm, 2.1 × 150 mm) column. The mobile phase consisted of a gradient between A (methanol–water–acetonitrile, 10:85:5 v/v) and B (methanol–water–acetonitrile, 90:5:5 v/v), both containing 0.1% ammonium acetate. The gradient program with
respect to the composition of B was as follows: 0–1 min, 50%; 1–8 min, 50–80; 8–15 min, 80–95%; and 15–17 min, 95%, with flow rate 0.2 ml min \(^{-1}\). The HPLC eluate was directly introduced to the electrospray ionization (ESI) source of a QTRAP5500 mass analyser (SCIEX), Redwood City, CA in the negative ion mode with the following conditions: curtain gas, GS1, and GS2: 35 psi; temperature: 600 °C; ion spray voltage: −2500 V; collision gas: low; declustering potential: −60 V; entrance potential: −7 V. The eluate was monitored via multiple reaction monitoring (MRM) to detect unique molecular ions. MRM was scheduled to monitor each transition for 120 s around the established retention time for each lipid mediator. Optimised collisional energies (18–35 eV) and collision cell exit potentials (7–10 V) were used for each MRM transition. Mass spectra for each detected lipid mediator were recorded using the Enhanced Product Ion (EPI) feature to verify the identity of the detected peak in addition to MRM transition and retention time match with the standard. Data were collected using Analyst 1.6.2 software, and the MRM transition chromatograms were quantified using MultiQuant software (both from SCIEX). The detection limit for MaR1 was 0.1 pg on the column, and the quantification limit was 3 pg on the column. The internal standard signals in each chromatogram were used for normalisation for recovery and relative quantitation of each analyte.

**Statistical analysis**

Data from mice were expressed as mean (standard error of the mean, SEM). Sample size calculation was performed with one-way analysis of variance (ANOVA) omnibus fixed-effects analysis using CyPower v 3.1 (http://www.gpower.hhu.de). Based on our previous work and preliminary studies, the effect size \(f\) of the primary analysis (trace fear conditioning and neuro-inflammation) between interventions was larger than 1. Thus, a study analysing four groups with five or more individuals per group would have 80% power to detect an effect size \(f\) of 0.835, which corresponds to the critical \(f\) value of 3.24. Differences between groups were compared using Student’s t-test (two groups), one-way ANOVA (multiple groups), or two-way ANOVA (multiple groups at multiple time points) followed by post hoc Bonferroni test (GraphPad version 7.0; GraphPad Software, San Diego, CA, USA). Statistical significance was defined as \(P<0.05\). For human CSF data, Friedman’s test was used to evaluate the change in CSF MaR1 levels over the full study period, and Wilcoxon signed rank tests were used to assess change between pairs of time points, because of the small sample size and skewed distribution of MaR1 levels in this cohort.

**Results**

**Pro-resolving and anti-inflammatory effects of maresin 1**

C57BL/6 and Ccr2\(^{RFP/+}\)\(\times\)Cx3cr1\(^{GFP/+}\) mice were continuously monitored during surgery for haemodynamic changes. No significant differences were observed in average heart rate (HR) and HR variability, and the percentage oxygen saturation (SpO\(_2\)) remained >95% throughout the procedure (not shown). All mice were included in the study.

We evaluated systemic changes in the expression of inflammatory cytokines and the process of bone healing up to 14 days after surgery (Fig. 1a). Surgery induced a systemic inflammatory response at 24 h, with significantly elevated levels of IL-6 \([113 (94) \text{ pg ml}^{-1}; P<0.02]\), IL-12 \([81 (20) \text{ pg ml}^{-1}; P=0.03]\), and CXCL1 \([287 (68) \text{ pg ml}^{-1}; P=0.01]\) compared with control mice (Fig. 1b–d). MaR1 prophylaxis reduced the levels of IL-6 and CXCL1 to baseline \([33 (3) \text{ pg ml}^{-1}; P=0.04]\) and 112 (8) \text{ pg ml}^{-1}, \(P=0.02\)] compared with the vehicle-treated surgery group (Fig. 1b,d) and attenuated IL-12 \(P=0.77\), which remained up-regulated in plasma up to 72 h after surgery \([68 (7) \text{ pg ml}^{-1}, P<0.01\] vs Control; Fig. 1c). Notably, MaR1 induced a sustained IL-10 response both at 24 h \([26 (1) \text{ pg ml}^{-1}\) and 72 h \([36 (4) \text{ pg ml}^{-1}\)] after surgery compared with vehicle-treated mice with osteotomy \([21 (1) \text{ pg ml}^{-1}, P=0.038\) and 26 (1) \text{ pg ml}^{-1}, P=0.097\], respectively; Fig. 1e). All of these cytokines levels returned to baseline by day 14 (Fig. 1b–e).

Systemic inflammation after infection or injury is well appreciated to affect behaviour and cognitive function. We tested hippocampal memory function using contextual fear conditioning in wild-type C57BL/6 and Ccr2\(^{RFP/+}\)\(\times\)Cx3cr1\(^{GFP/+}\) mice. Training was performed before any intervention, and working memory was established for the context after tone/shock pairing. Mice were tested in the same context but with no cues 72 h after surgery. Freezing time was significantly improved in animals receiving MaR1 treatment in both wild-type and Ccr2\(^{RFP/+}\)\(\times\)Cx3cr1\(^{GFP/+}\) mice (Fig. 1f and g; \(P<0.01\)), indicating better memory outcome after treatment. There was a significant effect on freezing time analysed using ANOVA. Locomotor activity at 72 h was also measured using an open field, and no differences in exploratory time were observed amongst groups (not shown). We also performed gene expression analyses in hippocampal tissues showing a protective effect of MaR1 on biological pathways of relevance to neurological system processes and cognition (Supplementary Fig. S1a and b).

Resolvins exert dual anti-inflammatory and pro-resolution effects, which help stimulate pathways to terminate inflammation and influence tissue repair.\(^ {19} \) We evaluated the effects of MaR1 on bone healing and callus formation after fracture and tibia pinning. Safranin O/Fast Green staining showed no statistically significant difference in callus formation in mice treated with MaR1 compared with vehicle on day 14 \(P=0.35\); Fig. 1h and i).

Maresin 1 prevented neuroinflammation and macrophage infiltration after surgery

We previously described changes in glial activation, including microglia and astrocytes, using this model of orthopaedic surgery.\(^ {13,21} \) Here we evaluated the effects of MaR1 on neuro-inflammation by measuring changes in GFAP and Iba-1 immunoreactivity in the hippocampus at 24 and 72 h after surgery. GFAP expression in the hippocampus was acutely dysregulated in the surgical group at 24 h (GFAP IR: 130 (18)% area in the Surgery group and 234 (11)% area in the Control group; \(P<0.01\)), returning to normal levels at 72 h (GFAP IR: 172 (23)% area; Fig. 2a and b). Mice treated with MaR1 (1 ng per mouse) retained the physiological features of classical astrocytes, with longer and more complex processes than mice treated with vehicle.

MaR1 also improved microglial/macrophage activation as measured by morphological changes in Iba-1 immunoreactivity. Surgery induced more stout microglia in the hippocampus at 24 h \([Iba1 IR: 224 (12)% \text{ area in the Surgery group and 128 (9)% area in the Control group; P<0.01\}]\), whereas mice treated with MaR1 retained a more ramified morphology reminiscent of the physiological state \([Iba1 IR: 144 (16)% \text{ area; Fig. 2a and c}\). Fewer activated microglia were evident at 72 h after surgery, with levels returning to baseline (Fig. 2a and c).
We used Ccr2RFP/þCx3cr1GFP/þ knock-in mice to differentiate between monocyte-derived macrophages and resident microglia cells. At 24 h after surgery, the peak of neuroinflammation, we recorded an increase in CCR2þ cells in the vehicle-treated surgery group [CCR2 IR: 4.6 (0.8)% area at 24 h, P < 0.01 vs Control and 2.4 (0.5)% area at 72 h, P < 0.01 vs Control; Fig. 2d and e], indicating the presence of monocyte-derived macrophages in the CA1–CA3 area of the hippocampus. Prophylaxis with MaR1 in Ccr2RFP/þCx3cr1GFP/þ mice limited macrophage infiltration in the brain parenchyma [CCR2 IR: 2.2 (0.4)% area at 24 h, P = 0.04 vs vehicle-treated group, and 0.6 (0.2)% area at 72 h, P = 0.02 vs vehicle-treated group; Fig. 2d and e]. Notably, macrophage infiltration was preceded by a reduction in claudin-5 (cld-5) expression, a key tight-junction protein critical to blood–brain barrier (BBB) integrity, at 12 h after surgery [cld5þ IR: 2.7 (0.7)% area in the Surgery group and 10 (1)% area in the Control group, P < 0.01; Fig. 2f and g]. Mice treated with MaR1 were protected from changes in cld-5 (Fig. 2f and g).

Maresin 1 reduced LPS-induced NF-κB nuclear translocation and superoxide generation in BMDMs

To better investigate the effects of MaR1 on CCR2þ monocytes, we cultured BMDMs in the presence of LPS with or without MaR1. LPS stimulation induced evident NF-κB p65 nuclear translocation [nuclear p65þ cells: 75 (4)% in the LPS group and 5 (1)% in the Control group, P < 0.01; Fig. 3a and b] and TNF-α release in the culture medium [685 (52) pg ml⁻¹ in the LPS group and 49 (1) pg ml⁻¹ in the Control group, P < 0.01; Fig. 3c]. Co-incubation with MaR1 (10 nM) significantly attenuated LPS-induced NF-κB p65 nuclear translocation in BMDMs [nuclear p65þ cells: 16 (3)% vs LPS group, Fig. 3a and b], and partly reduced TNF-α levels in the culture medium [494 (49) pg ml⁻¹, P = 0.01 vs LPS group; Fig. 3c]. MaR1 significantly decreased LPS-induced NADPH oxidase activity in BMDMs at 24 h, indicated by the lower superoxide generation [Chemiluminescence Unit, % Control: 213 (15)% in the LPS group and 155 (8)% in the LPS + MaR1 group, P < 0.01; Fig. 3d]. In addition, enhancement of PD-L1 and CD86 by LPS stimulation was significantly reduced by co-incubation of MaR1 (Fig. 3e and f). MaR1 treatment did not significantly affect PD-L2 and CD206 changes in response to anti-inflammatory macrophage stimulation (IL-4/IL-10/TGF-β; Fig. 3g and h).

Human CSF maresin 1 levels before and after non-cardiac surgery

To determine the potential role of endogenous MaR1 in resolving neuroinflammation in patients at risk for developing PNDs, we measured CSF MaR1 levels in 11 older adults before and after major non-cardiac, non-neurological surgery. Baseline preoperative data and postoperative cognitive performance data in these 11 patients are presented in Table 1. CSF MaR1 levels were detectable in all 11 patients before and after surgery, although we detected no statistically significant overall change in MaR1 levels in this pilot patient sample [Fig. 4a; P = 0.53], nor between any pair of study time points. A scatterplot of these data is presented in Supplementary Fig. S2.
Discussion

In the present study, maresin 1, a novel SPM synthetised by macrophages during the inflammatory resolution phase, provides distinct anti-inflammatory and pro-resolving effects by limiting excessive neuroinflammation and facilitating postoperative recovery (Fig. 4b). Dysregulated inflammation and failed resolution is now a well-recognised phenomenon in a variety of disease models. Trauma initiates an immune response contributing to the overall extent of injury and outcome. We previously reported a key role of TNF-α in initiating a cytokine cascade, contributing to the onset of cognitive decline after surgery. TNF-α is one of the earliest cytokine to appear after damage and is responsible for the production of many mediators, including IL-1β and IL-6. Our results show that MaR1 attenuates release of systemic pro-inflammatory cytokines and TNF-α in macrophages. Besides reducing phosphorylation and nuclear translocation of the NF-κB p65 subunit, a critical component in the regulation of the inflammatory process, MaR1 also attenuated superoxide generation in activated macrophages. The synergism/crosstalk between pro-inflammatory cytokines and oxidative stress in the pathophysiology of cognitive decline remains to be further explored. MaR1 exerts protective effects after vascular injury through modulation of NADPH-oxidase 4 (NOX-4) and NF-κB activity in vascular smooth muscle cells. This is consistent with our current findings in BMDMs and previous reports that other SPMs reduced reactive oxygen species production.

Maresins are stereotypical pro-resolving mediators that exert dual actions after trauma or infection by limiting polymorphonuclear leukocyte entry and stimulating effec-

Fig 2. Maresin 1 prevents hippocampal neuroinflammation by regulating macrophage infiltration and claudin-5 (clsd-5) expression at the blood–brain barrier. (a) Representative confocal images immunostained for GFAP and Iba1 at 24 h and 72 h. (b, c) Quantification of GFAP and Iba1 immunostaining. Surgery affected astrocytic processes and microglia/macrophage activation peaking at 24 h, with mild changes at 72 h. MaR1 pretreatment significantly reduced surgery-induced neuroinflammation. (d) Representative z-stack images from Ccr2RFP+/Cx3cr1GFP/+ at 24 h show macrophage infiltration (red) and residency microglia (green) in the CA1–CA3 hippocampus region. (e) Treatment with MaR1 reduced macrophage infiltration into hippocampus at 24 and 72 h after surgery. (f, g) Representative images for clsd-5 immunostaining. MaR1 prevented clsd-5 downregulation on the hippocampal vasculature, restoring the expression to control levels. Scale bar: 50 μm. Data expressed as mean (SEM). *P<0.05, **P<0.01; n=3–5 per group. C, Control; DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; MaR1, Maresin 1; slm, stratum lacunosum-moleculare; pyr, pyramidale; sr, stratum radiatum; S, Surgery; SEM, standard error of the mean.
These findings have clinical relevance to several common complications in the postoperative period, including prevention of delirium and postoperative cognitive dysfunction (POCD), and improvement of bone healing. The regenerative properties of MaR1 were initially reported using a surgical model in planaria, a worm with the intrinsic ability to regenerate. We found that in rodents MaR1 does not impair the process of bone repair but actually enhances callus formation. We also found that MaR1 increased the systemic levels of IL-10 with a long-lasting trend up to postoperative day 14. IL-10 has anti-inflammatory actions but its contribution to the healing process is not fully established. The possible anti-inflammatory actions that IL-10 has on the pro-inflammatory niche, potentially attenuating neuroinflammation and cognitive decline, might be different from the pro-resolving effects that a ‘resolution agonist’ have to restore physiological function in the tissue. Notably, maresins were recently shown to interact with stem cells, limiting chronic inflammation and improving wound healing in diabetes mellitus and spinal cord injury.

We describe an attenuation of classically associated M1 markers in macrophages stimulated by LPS, including expression of miR155 in hippocampus, which has an established role in controlling Toll-like receptors (TLR) and NF-κB signalling. Other SPMs aside from MaR1 have been shown to modify miRNAs, reduce nuclear translocation of NF-κB, and downregulate phospho-IκB, both in murine and human macrophages. Although we could not detect significant changes in M2 markers in vitro, it has been shown that MaR1 enhances ‘M2-like’ polarisation in vivo. This switch to an ‘M2-like’ profile may account for the multiple organoprotective actions of MaR1 that were also evident in our model, including promotion of tissue healing and attenuation of CCR2+ cell infiltration in the hippocampus. This study further illustrates the bidirectional communication between the periphery and brain, and the importance of macrophages in mediating CNS pathology. BBB dysfunction may represent a key mechanism contributing to neurological dysfunction and complications after surgery, and provides a

**Fig 3.** Maresin 1 effects on bone marrow-derived macrophages (BMDMs). (a) Representative images of immunostaining of NF-κB in BMDMs. Stimulated with 10 ng ml⁻¹ LPS for 2 h. (b) 2 h of LPS stimulation (10 ng ml⁻¹) significantly increased NF-κB nuclear translocation in BMDMs. (c) LPS caused significant increase of TNF-α release from BMDMs after 24 h stimulation, which was reduced by co-application of MaR1 (10 nm). (d) NADPH oxidase mediated superoxide production in BMDMs was significantly increased after 24 h of LPS stimulation, which was inhibited by MaR1 co-application. (e–h) MaR1 reduced LPS-induced PD-L1 and CD86 expression in BMDMs at 24 h. No significant effect of MaR1 on PD-L2 and CD206 expression in BMDMs stimulated by M2 polarisation cytokines (IL-4/IL-10/TGF-β). Data are expressed as mean (SEM). *P<0.05, **P<0.01; n=3–5 per group. CLU, chemiluminescence unit; IL, interleukin; LPS, lipopolysaccharide; MaR1, Maresin 1; MFI, median fluorescence intensity; NADPH, nicotinamide adenine dinucleotide phosphate; SEM, standard error of the mean; TNF, tumour necrosis factor.
potential pathway for peripheral macrophage access to the brain. This ‘passive’ diffusion through a relative permeable barrier may account for the subsequent neuroinflammatory response.\textsuperscript{13,14} MaR1 prevented damage to the BBB via regulation of the expression of tight junctions (cld-5) and expression of endothelial microRNAs, such as miR126, that are implicated in response to stress and inflammation.\textsuperscript{41} This is consistent with the effects of resolvins and maresins on endothelial function and vasculature homeostasis, regulating diapedesis and stimulating vasoprotective and anti-thrombotic mediators.\textsuperscript{19,42} In addition to reducing macrophage trafficking and neuroinflammation after surgery, MaR1 also restored memory function in both wild-type and Ccr\textsuperscript{2FP/}-Cx3cr\textsuperscript{1GFP/} mice, suggesting that block of peripheral cell influx into the brain is a potential avenue to treat surgery-induced cognitive disorders. Evidence of de novo synthesis of pro-inflammatory cytokines and chemokines (including MCP-1) in the hippocampus has been reported, suggesting ‘active’ recruitment of peripheral monocytes into the CNS.\textsuperscript{13,14} The mechanisms whereby systemic trauma contributes to changes in brain physiology require further investigation. It is suggested that CCR2\textsuperscript{+} Ly6C\textsuperscript{hi} monocytes (as labelled in the CCR2-RFP knock-in mouse) initiate and sustain neuroinflammatory responses.\textsuperscript{43} Specific CCR2 subsets may be vital to the recovery process and local anti-inflammatory actions.\textsuperscript{44}

Lipoxins, resolvins, protectins, and maresins were recently identified in human peripheral blood and lymphoid organs through metabololipidomics.\textsuperscript{45} We detected MaR1 in the CSF of older patients before and after non-cardiac, non-neurological surgery. Although we found no evidence of overall change in MaR1 levels in this limited cohort, two patients exhibited markedly greater change than others. There are potentially important differences between the subset of patients with large 24 h increases in MaR1 and those without preoperative factors commonly associated with cognitive outcomes (age, baseline cognition, years of education). Future studies with larger sample sizes might identify patient and procedural factors associated with postoperative CSF MaR1 increase. Such future studies may provide novel insights into the role of SPMs as biomarkers (such as for PND severity) in the perioperative period.

Limitations in our study include the specific interrogation of MaR1 signalling after surgery. Although MaR1 is a primary

### Table 1 Patient characteristics and cognitive data.

| Characteristic                      | All (n=11) |
|------------------------------------|------------|
| Age, range (yr)                    | 60–80      |
| Male sex, n (%)                    | 10 (91)    |
| ASA physical status, n (%)         |            |
| 2                                  | 3 (27)     |
| 3                                  | 7 (64)     |
| 4                                  | 1 (9)      |
| Surgical service, n (%)            |            |
| Thoracic                          | 1 (9)      |
| General surgery                    | 3 (27)     |
| Urology                            | 7 (64)     |
| Surgery duration (min incision to end procedure), median (Q1, Q3) | 215 (117, 297) |
| Years of education, median (Q1, Q3) | 16 (14, 20) |
| Mini-Mental Status Exam Score      |            |
| Preoperative, median (Q1, Q3)      | 29 (27, 30) |
| 6-week, median (Q1, Q3)            | 29 (27, 29) |
| Cognitive index                    |            |
| Preoperative, mean (SD)            | 0.23 (0.80) |
| 6-week, mean (SD)                  | 0.29 (0.74) |

![Fig 4. Maresin 1 levels in CSF before, 24 h, and 6 weeks after major non-cardiac, non-neurologic surgery in older patients (age ≥60 yr). (a) Each line represents a single patient. Diagonal cross marks on the X and Y axes indicate non-linearity/scale discontinuity. n=11. (b) Working model for MaR1 protection in PNDs. Pre-treatment with MaR1 regulated excessive inflammation from circulating macrophage by reducing NF-κB activation, oxidative stress, pro-inflammatory cytokine release, overall contributing to a ‘M2-like’ switch. This systemic milieu did not impair fracture healing or cause signs of immunosuppression. In fact, these systemic effects prevented loss of cld-5 expression at the blood–brain barrier (BBB) and macrophage infiltration into the brain parenchyma. Overall, dampening the post-operative neuroinflammation leads to improved cognitive function. CSF, cerebrospinal fluid; IL, interleukin; MaR1, Maresin 1; NF-κB, nuclear factor-kappa B; PNDs, perioperative neurocognitive disorders; ROS, reactive oxygen species.](image-url)
product of monocytic cell types, the ligand–receptor interactions are not yet fully defined. MaR1 can lead to complex metabolites that exert different temporal functions in the resolution of inflammation. This bioactive metabolome impacts multiple signalling pathways (anti-inflammation, regeneration, anti-nociception, etc.) which require further investigation in the perioperative context. For example, we recently described the analgesic effects of MaR1 at significantly higher doses (500 ng) and different routes of administration, including intrathecal. This suggests a different mode of action and effects on cell types that could be harnessed for different therapeutic needs. Earlier strategies aimed at attenuating the neuroinflammatory response after surgery have focused on dampening the innate immune response, with potential implications to both host defense and organ function. SPMs display potent anti-inflammatory actions without being immunosuppressive. Although clinical studies are identifying inflammatory biomarkers implicated with cognitive impairment after surgery, the role of neuroinflammation in PNDs needs to be further established.

In summary, our results identify MaR1 as a novel regulator of postoperative inflammation and ensuing cognitive decline through the modulation of macrophage trafficking and activity. These findings suggest a novel therapeutic potential for SPMs in preventing surgery-induced cognitive decline, including facilitating postoperative recovery, and provide evidence for detection in human CSF after surgery.

Authors’ contributions
Bone healing experiments: PTN, ASC.
Gene array: SM.
Cell culture assays: TY, GX, M. Carlström, X-MZ.
Human study: M. Cooter, MB.
Lipidomic analyses: KRM.
Neuroinflammation and behavioural experiments: TY, GX, NT.
Provided key reagents: M. Carlström, RAH, KA.
Data analysis: all authors.
Drafting of the manuscript: TY, NT.
All authors participated in the revision and gave approval to the final version of the manuscript. All authors contributed to the study design.

Acknowledgements
The authors thank M. Goiny (senior researcher, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden) for excellent technical support.

Funding
Research grant program of the European Society of Anaesthesiology, Loo och Has Ostermans Foundation for Medical Research, Karolinska Institutet Foundations and National Institute of Aging R01AG057525 and R21AG055877 to NT National Institute of Aging R03 AG059918, R03 AG057022, AG028716, a Jahnigen Scholars Award, and an IARS Mentored Research Award to MB. MB also acknowledges additional support from National Center for Advancing Translational Sciences Clinical and Translational Science Award UL1TR001117 (Contact PI: Dr. Ebony Boulware) and from National Institute of Aging F30 AG028716 (Contact Pis: Drs. Ken Schmader, Miriam Morey, and Heather Whitson). National Institute of Neurological Disorders and Stroke R35 097976 to KA. Lipidomic analysis is supported by National Center for Research Resources grant S10RR027926 (KRM).

Declaration of interest
The authors declare they have no conflicts of interest.

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.bja.2018.10.062.

References
1. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428–35
2. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014; 510: 92–101
3. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest 2018; 128: 2657–69
4. Perretti M, Leroy X, Bland EJ, Montero-Melendez T. Resolution pharmacology: opportunities for therapeutic innovation in inflammation. Trends Pharmacol Sci 2015; 36: 737–55
5. Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206: 15–23
6. Serhan CN, Dalli J, Karamnov S, et al. Macrophage pro-resolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J 2012; 26: 1755–65
7. Abdulnour RE, Dalli J, Colby JK, et al. Maresin 1 biosynthesis during platelet–neutrophil interactions is organ-protective. Proc Natl Acad Sci U S A 2014; 111: 16526–31
8. Wang CW, Colas RA, Dalli J, et al. Maresin 1 biosynthesis and proresolving anti-infective functions with human-localized aggressive periodontitis leukocytes. Infect Immun 2015; 84: 658–65
9. Colas RA, Dalli J, Chiang N, et al. Identification and actions of the maresin 1 metabolome in infectious inflammation. J Immunol 2016; 197: 4444–52
10. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity 2014; 41: 21–35
11. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 2003; 4: 103–12
12. D’Mello C, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci 2009; 29: 2089–102
13. Terrando N, Eriksson LI, Ryu JK, et al. Resolving postoperative neuroinflammation and cognitive decline. Ann Neurol 2011; 70: 986–95
14. Degos V, Vacas S, Han Z, et al. Depletion of bone marrow-derived macrophages perturbs the innate immune response to surgery and reduces postoperative memory dysfunction. Anesthesiology 2013; 118: 527–36
15. Evered I, Silbert B, Knopman D, et al. Recommendations for the nomenclature of cognitive changes associated with anesthesia and surgery. Br J Anaesth 2018; 65: 1248–57
16. Tan H, Cao J, Zhang J, Zuo Z. Critical role of inflammatory cytokines in impairing biochemical processes for learning
and memory after surgery in rats. J Neuroinflamm 2014; 11: 93

17. Hu J, Feng X, Valdearcos M, et al. Interleukin-6 is both necessary and sufficient to produce perioperative neurocognitive disorder in mice. Br J Anaesth 2018; 120: 537–45

18. Soriano SG, Vutskits L, Jevtovic-Todorovic V, Hemmings HC, Neurotoxicology BJ A, Neuroplasticity Study G. Thinking, fast and slow: highlights from the 2016 BJA seminar on anaesthetic neurotoxicity and neuroplasticity. Br J Anaesth 2017; 119: 443–7

19. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349–61

20. Zhang MD, Barde S, Yang T, et al. Orthopedic surgery modulates neuropeptides and BDNF expression at the spinal and hippocampal levels. Proc Natl Acad Sci U S A 2016; 113: E6686–95

21. Terrando N, Gomez-Galan M, Yang T, et al. Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline. FASEB J 2013; 27: 3564–71

22. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44–57

23. Giattino CM, Gardner JE, Sbahi FM, et al. Intraoperative fentanal alpha-band power correlates with preoperative neurocognitive function in older adults. Front Syst Neurosci 2017; 11: 24

24. Wang X, Zhu M, Hjorth E, et al. Resolution of inflammation is altered in Alzheimer’s disease. Alzheimers Dement 2015; 11: 40–50 e1–2

25. Nathan C, Ding A. Nonresolving inflammation. Cell 2010; 140: 871–82

26. Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze M. Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A 2010; 107: 20518–22

27. Chatterjee A, Sharma A, Chen M, Toy R, Mottola G, Conte MS. The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells. PloS One 2014; 9: e113480

28. Titos E, Rius B, Gonzalez-Periz A, et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 2011; 187: 5408–18

29. Marcon R, Bento AF, Dutra RC, Bica MA, Leite DF, Calixto JB. Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J Immunol 2013; 191: 4288–98

30. Gu J, Luo L, Wang Q, et al. Maresin 1 attenuates mitochondrial dysfunction through the ALX/CAMP/ROS pathway in the cecal ligation and puncture mouse model and sepsis patients. Lab Invest 2018

31. Zhang L, Terrando N, Xu ZZ, et al. Distinct analgesic actions of DHA and DHA-derived specialized pro-resolving mediators on post-operative pain after bone fracture in mice. Front Pharmacol 2018; 9: 412

32. Serhan CN, Chiang N. Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol 2013; 13: 632–40

33. Jetten N, Roumans N, Gijbels MJ, et al. Wound administration of M2-polarized macrophages does not improve murine cutaneous healing responses. PloS One 2014; 9: e102994

34. Hong S, Lu Y, Tian H, et al. Maresin-like lipid mediators are produced by leukocytes and platelets and rescue reparative function of diabetes-impaired macrophages. Chem Biol 2014; 21: 1318–29

35. Francos-Quijorna I, Santos-Nogueira E, Gronert K, et al. Maresin 1 promotes inflammatory resolution, neuroprotection, and functional neurological recovery after spinal cord injury. J Neurosci 2017; 37: 11731–43

36. Tili E, Michaille JJ, Gimino A, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007; 179: 5082–9

37. Quinn SR, O’Neill LA. A trio of microRNAs that control Toll-like receptor signalling. Int Immunol 2011; 23: 421–5

38. Li Y, Dalli J, Chiang N, Baron RM, Quintana C, Serhan CN. Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators. Immunity 2013; 39: 885–98

39. Dalli J, Zhu M, Vlasenko NA, et al. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J 2013; 27: 2573–83

40. Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurologic diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci 2018; 19: 283–301

41. Schober A, Nazari-Jahantigh M, Wei Y, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014; 20: 368–76

42. Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009; 461: 1287–91

43. Saederup N, Cardona AE, Croft K, et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 2010; 5: e13693

44. Shechter R, London A, Varol C, et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009; 6: e1000113

45. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 2014; 307: C39–54